TABLE 2.
Tumor Characteristics Based on Cirrhosis Status
| Trait | Overall | No Cirrhosis | Cirrhosis | P Value |
|---|---|---|---|---|
| N = 1,382 | n = 470 | n = 770 | ||
| Alpha‐fetoprotein (ng/dL) (n = 762) | 16.0 (4.4, 404.1) | 24.5 (4.2, 478.7) | 13.4 (4.5, 374.0) | 0.64 |
| Maximum tumor size (cm) (n = 917) | 4.0 (2.3, 7.6) | 5.7 (3.5, 9.8) | 3.3 (2.1, 6.0) | <0.001 |
| Tumor number (n = 922) | 1.0 (1.0, 2.0) | 1.0 (1.0, 2.0) | 1.0 (1.0, 2.0) | 0.01 |
| Unifocal cancer (n = 922) | 68.6% | 74.4% | 66.3% | 0.005 |
| Within Milan criteria (n = 859) | 52.5% | 55.4% | 53.1% | 0.46 |
| BCLC stage (n = 643) | ||||
| 0 | 6.2% | 5.4% | 6.0% | |
| A | 33.1% | 23.5% | 37.1% | <0.001 |
| B | 32.5% | 46.2% | 26.7% | |
| C | 21.5% | 24.2% | 19.8% | |
| D | 6.8% | 0.7% | 10.4% | |
| Treatment | ||||
| Any cancer treatment | 71.2% | 76.0% | 70.5% | 0.042 |
| Resection | 24.6% | 39.4% | 14.7% | <0.001 |
| Liver transplant | 4.1% | 0.0% | 6.9% | <0.001 |
| Ablation | 8.8% | 3.4% | 12.6% | <0.001 |
| Transarterial/radiation therapy | 43.2% | 35.4% | 50.3% | <0.001 |
| Systemic | 6.4% | 7.0% | 7.3% | 0.91 |
| Supportive care only | 28.8% | 24.% | 29.5% | 0.042 |
Data are depicted as mean ± SD, median (interquartile range), or percentages. Some patients underwent multiple treatments.